| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0049-0172(92)90022-6 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:0049017292900226?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:0049017292900226?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1604325 |
| P2093 | author name string | A. van der Heide | |
| H. J. Dinant | |||
| J. W. Bijlsma | |||
| J. W. Jacobs | |||
| van der Heide A | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis | Q33443978 | ||
| Auranofin or D-penicillamine in the treatment of rheumatoid arthritis | Q33446440 | ||
| Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis | Q33557710 | ||
| A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis | Q33561025 | ||
| What should we hope to achieve when treating rheumatoid arthritis? | Q33561548 | ||
| A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine | Q33561669 | ||
| Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens | Q33561838 | ||
| Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | Q33563148 | ||
| Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. | Q38140867 | ||
| Critical review of clinical assessment techniques for rheumatoid arthritis trials: new developments | Q38735134 | ||
| A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis | Q41155508 | ||
| Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial | Q41451581 | ||
| Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis--a comparative study | Q41913462 | ||
| Radiological progression in rheumatoid arthritis: do D-penicillamine and hydroxychloroquine have different effects? | Q41944088 | ||
| Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine | Q41944917 | ||
| Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study | Q41946029 | ||
| Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation | Q42162247 | ||
| Measuring health status in arthritis. The arthritis impact measurement scales | Q51270176 | ||
| Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis. | Q52490070 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires | Q57169726 | ||
| Which traditional measures should be used in rheumatoid arthritis clinical trials? | Q57244960 | ||
| A COMPARISON OF THE ABILITY OF 28 ARTICULAR INDICES TO DETECT AN INDUCED FLARE OF JOINT INFLAMMATION IN RHEUMATOID ARTHRITIS | Q61912662 | ||
| Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response | Q61912668 | ||
| Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments. | Q64978151 | ||
| Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group | Q67285449 | ||
| Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis | Q68130741 | ||
| What are the 'best' measurements for monitoring patients during short-term second-line therapy? | Q68255501 | ||
| Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial | Q68498755 | ||
| Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study | Q68501632 | ||
| Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate | Q68542189 | ||
| OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study | Q68634224 | ||
| Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial | Q68956193 | ||
| Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis | Q69370492 | ||
| Efficacy of tests used to monitor rheumatoid arthritis | Q69374721 | ||
| Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial | Q69892485 | ||
| A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis | Q69919512 | ||
| Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis | Q69926907 | ||
| Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures | Q69941100 | ||
| Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis | Q70311989 | ||
| Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study | Q70346578 | ||
| A three year comparative multicenter study of auranofin (AF) and gold sodium thiomalate (GST) in the treatment of rheumatoid arthritis (RA) | Q70369830 | ||
| The cost effectiveness of auranofin: results of a randomized clinical trial | Q70382096 | ||
| Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study | Q70389928 | ||
| Preference for endpoint measures in clinical trials: results of structured workshops | Q70606506 | ||
| The assessment of disease activity in rheumatoid arthritis using a multivariate analysis | Q70742372 | ||
| Toward an understanding of patient outcome measurement | Q71759226 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clinical trial | Q30612 |
| rheumatoid arthritis | Q187255 | ||
| rheumatology | Q327657 | ||
| Anesthesiology and pain medicine | Q26842311 | ||
| P304 | page(s) | 287-294 | |
| P577 | publication date | 1992-04-01 | |
| P1433 | published in | Seminars in Arthritis and Rheumatism | Q15761553 |
| P1476 | title | The impact of endpoint measures in rheumatoid arthritis clinical trials | |
| P478 | volume | 21 |
| Q40626172 | A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis |
| Q33565974 | Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis |
| Q35549353 | Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands |
| Q37428914 | Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists |
| Q34550160 | Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide |
| Q64921478 | Measurement of morning stiffness in rheumatoid arthritis clinical trials. |
| Q40777923 | Outcome measurement in scleroderma clinical trials |
| Q33565578 | Self report functional disability scores and the use of devices: two distinct aspects of physical function in rheumatoid arthritis |
| Q40518164 | The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies |
Search more.